AZD-5991,2143061-81-6

MCE 的所有产品仅用作科学研究或药证申报，我们不为任何个人用途提供产品和服务。

AZD-5991

CAS No. : 2143061-81-6

MCE 国际站：AZD-5991

产品活性：AZD-5991 是一种有效的选择性 Mcl-1 抑制剂，FRET 实验检测的 IC₅₀ 为 0.7 nM， SPR 实验检测的 K_d 为 0.17 nM。

研究领域：Apoptosis

作用靶点：Bcl-2 Family

In Vitro: The selectivity of AZD-5991 is evaluated against pro-survival Bcl-2 family members using FRET assays. AZD-5991 is selective for Mcl-1 (IC₅₀ 0.72 nM, K_i=200 pM) vs. Bcl-2 (IC₅₀=20 µM, K_i=6.8 µM), Bcl-xL (IC₅₀=36 µM, K_i=18 µM), Bcl-w (IC₅₀=49 µM, K_i=25 µM), and Bfl-1 (IC₅₀=24 µM, K_i=12 µM). MOLP-8, MV4-11, and NCI-H23 cells are treated with AZD5991 (EC₅₀=0.033, 0.024, 0.19 µM, respectively).AZD5991 binds directly to Mcl-1 and induces rapid apoptosis in cancer cells, most notably myeloma and acute myeloid leukemia, by activating the Bak-dependent mitochondrial apoptotic pathway. AZD5991 reduces the levels of Mcl-1 protein in AZD5991-sensitive but not in AZD5991-resistant MM cell lines further supporting the notion that activation of caspases by AZD5991 reduces Mcl-1 protein levels in AZD5991-sensitive cell lines.

In Vivo: A single intravenous (i.v.) dose of AZD5991 leads to a dose-dependent antitumor effect ranging from tumor growth inhibition (TGI) to tumor regression (TR). Ten days after treatment, AZD5991 shows 52% and 93% TGI (p<0.0001) at 10 and 30 mg/kg, respectively. At the same time point, AZD5991 at 60 mg/kg leads to 99% TR with no detectable tumors in 6 out of 7 mice, while complete TR is seen in 7 out of 7 mice in the 100 mg/kg dose group. AZD5991 also shows a dose-dependent duration of response with tumors in the 100 mg/kg group growing back later than those in the 60 mg/kg group. The magnitude of in vivo tumor efficacy is correlated with activation of caspase-3 in the tumor and concentration of AZD5991 in plasma. Treatment with AZD5991 was well tolerated at all dose levels with no significant body weight loss. A single dose of AZD5991 36 days after the first dose causes tumor regression in 4 out of 4 mice. In mice dosed with AZD5991 at 100 mg/kg on day 0 and day 1, tumors grow back later than those dosed with a single dose of AZD5991 at the same dose level.

相关产品：Drug Repurposing Compound Library Plus  |  Clinical Compound Library Plus  |  Bioactive Compound Library Plus  |  Apoptosis Compound Library  |  Anti-Cancer Compound Library  |  Clinical Compound Library  |  Drug Repurposing Compound Library  |  Anti-Blood Cancer Compound Library  |  Mitochondria-Targeted Compound Library  |  Targeted Diversity Library  |  Highly Selective Inhibitors Library  |  Venetoclax  |  Navitoclax  |  Polyinosinic-polycytidylic acid  |  S63845  |  ABT-737  |  A-1331852  |  BT2  |  Chlorin e6  |  A-1155463  |  MIK665  |  Estradiol benzoate  |  BAI1  |  Benzbromarone  |  Obatoclax Mesylate  |  Digitoxin  |  Chelerythrine chloride  |  BI-3802  |  AZD4320  |  Dehydrocorydaline  |  WEHI-539 hydrochloride  |  Tapotoclax  |  Amantadine  |  A-1210477  |  Gambogic Acid  |  BTSA1  |  Bax inhibitor peptide V5  |  UMI-77  |  Cardamonin  |  TCPOBOP  |  Daphnetin

热门产品线：重组蛋白  |  化合物库  |  天然产物  |  荧光染料  |  PROTAC  |  同位素标记物

Trending products：Recombinant Proteins  |  Bioactive Screening Libraries  |  Natural Products  |  Dye Reagents  |  PROTAC  |  Isotope-Labeled Compounds